Accéder au contenu
Merck

Multilocus sequence typing reveals genetic diversity of carbapenem- or ceftazidime-nonsusceptible Pseudomonas aeruginosa in China.

Antimicrobial agents and chemotherapy (2013-08-14)
Jingshu Ji, Jie Wang, Zhihui Zhou, Haiping Wang, Yan Jiang, Yunsong Yu
RÉSUMÉ

It is unclear whether the genetic background of drug-resistant Pseudomonas aeruginosa was disseminated from a certain clone. Thus, we performed MLST (multilocus sequence typing) of 896 P. aeruginosa isolates that were nonsusceptible to imipenem, meropenem, or ceftazidime. This revealed 254 sequence types (STs), including 104 new STs and 34 STs with novel alleles. Thirty-three clonal complexes and 404 singletons were found. In conclusion, drug-resistant P. aeruginosa clones can be developed from diverse genetic backgrounds.

MATÉRIAUX
Référence du produit
Marque
Description du produit

USP
Ceftazidime pentahydrate, United States Pharmacopeia (USP) Reference Standard
Ceftazidime, European Pharmacopoeia (EP) Reference Standard
Ceftazidime for peak identification, European Pharmacopoeia (EP) Reference Standard